Stayble receives its first approved patent for the treatment of herniated discs
Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has approved the Company's patent for the treatment of herniated discs with STA363. This approval is a significant milestone for the Company and follows a previous positive international search report from European authorities. With these advancements, we see strong potential to obtain several additional national patent approvals.The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides